Regulatory Information
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Therapeutic
Prescription Only
Formulation Information
TABLET
**RECOMMENDED DOSES:** Orally administered: Dosage requirements are variable and must be individualized on the basis of the disease under treatment and the response of the patient. Adults : 5–60 mg daily in divided doses or as a single daily or double dose on alternate days. In long term therapy, dosage should be maintained at not more than 7 mg daily whenever possible. Children: As directed by physician. For short term treatment of not more than 2 weeks, as it may lead to growth retardation in children.
ORAL
Medical Information
**INDICATIONS:** For the suppression of inflammatory and allergic disorders and for the treatment of conditions for which corticosteroid therapy is indicated except in adrenal-deficiency states.
**CONTRA-INDICATIONS:** Patients with active or doubtfully quiescent tuberculosis. In the presence of acute infections, including herpes zoster and herpes simplex, ulceration of the eye. Patients with peptic ulcer, osteoporosis, pyschoses or severe psychoneuroses.
H02AB06
prednisolone
Manufacturer Information
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
PT Actavis Indonesia
Active Ingredients
Documents
Package Inserts
Att 6 AAAM6055 Dhasolone PI P Clean.pdf
Approved: March 16, 2021